» Articles » PMID: 40022086

Exosomal LncRNA Mir100hg from Lung Cancer Stem Cells Activates H3K14 Lactylation to Enhance Metastatic Activity in Non-stem Lung Cancer Cells

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2025 Feb 28
PMID 40022086
Authors
Affiliations
Soon will be listed here.
Abstract

The mean survival of metastatic lung adenocarcinoma is less than 1 year, highlighting the urgent need to understand the mechanisms underlying its high mortality rate. The role of Extracellular vesicles (EVs) in facilitating the interactions between cancer cells and the metastatic microenvironment has garnered increasing attention. Previous studies on the role of EVs in metastasis have been primarily focused on cancer cell-derived EVs in modulating the functions of stromal cells. However, whether cancer stem cells (CSCs) can alter the metastatic properties of non-CSC cells, and whether EV crosstalk can mediate such interaction, have not been demonstrated prior to this report. In the present study, we integrated multi-omics sequencing and public database analysis with experimental validation to demonstrate, for the first time, the exosomal Mir100hg, derived from CSCs, could enhance the metastatic potential of non-CSCs both in vitro and in vivo. Mechanistically, HNRNPF and HNRNPA2B1 directly binds to Mir100hg, facilitating its trafficking via exosomes to non-CSCs. In non-CSCs, Mir100hg upregulates ALDOA expression, subsequently leading to elevated lactate production. Consequently, the increased lactate levels enhance H3K14 lactylation by 2.5-fold and promote the transcription of 169 metastasis-related genes. This cascade of events ultimately results in enhanced ALDOA-driven glycolysis and histone lactylation-mediated metastatic potential of non-CSC lung cancer cells. We have delineated a complex regulatory network utilized by CSCs to transfer their high metastatic activity to non-CSCs through exosomal Mir100hg, providing new mechanistic insights into the communication between these two heterogeneous tumor cell populations. These mechanistic insights provide novel therapeutic targets for metastatic lung cancer, including HNRNPF/HNRNPA2B1-mediated Mir100hg trafficking and the histone lactylation pathway, advancing our understanding of CSC-mediated metastasis while suggesting promising strategies for clinical intervention.

References
1.
Jiang J, Huang D, Jiang Y, Hou J, Tian M, Li J . Lactate Modulates Cellular Metabolism Through Histone Lactylation-Mediated Gene Expression in Non-Small Cell Lung Cancer. Front Oncol. 2021; 11:647559. PMC: 8208031. DOI: 10.3389/fonc.2021.647559. View

2.
Zhu R, Ye X, Lu X, Xiao L, Yuan M, Zhao H . ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab. 2024; 37(2):361-376.e7. DOI: 10.1016/j.cmet.2024.10.015. View

3.
Pang Y, Wu J, Li X, Wang C, Wang M, Liu J . NEAT1/miR‑124/STAT3 feedback loop promotes breast cancer progression. Int J Oncol. 2019; 55(3):745-754. DOI: 10.3892/ijo.2019.4841. View

4.
Oikawa D, Shimizu K, Tokunaga F . Pleiotropic Roles of a KEAP1-Associated Deubiquitinase, OTUD1. Antioxidants (Basel). 2023; 12(2). PMC: 9952104. DOI: 10.3390/antiox12020350. View

5.
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S . Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018; 8(14):3932-3948. PMC: 6071523. DOI: 10.7150/thno.25541. View